No­vo Nordisk has end­ed work ear­ly on two more late-stage stud­ies of its IL-6 in­hibitor zil­tivekimab af­ter the stud­ies’ da­ta mon­i­tor­ing com­mit­tee de­ter­mined there was lit­tle chance of them suc­ceed­ing...